REFERENCIAS BIBLIOGRÁFICAS

1.- GROCHEIDE AND PIERRE VAN DAMME. Prevention and control of hepatitis B in the community. World Health Organization. Communicable Diseases Series N.°1, 1996; 1: 68.

2.- World Health Organization. Progress in the control of viral hepatitis: Memorandum from WHO Meeting. Bull World Organ 1988; 66: 443-445.

3.- LJUNGGREN KE, PATARROYO ME, ENGLE R et al. Viral hepatitis in Colombia: A study of the hepatitis of the Sierra Santa Marta. Hepatology 1985; 5: 299-304.

4.- FONSECA JC, SIMONETTI JP, FERREIRA LC. Aspectos epidemiológivos da infeccao pelo virus da hepatitis Delta (HDV) e portadores asintomaticos do virus da Hepatite B (HBV) no estado do Amazonas, Brasil. Rev Inst Med Trop 1986; 19:120.

5.- HADLER SC, MONSON M, PONZETTO A, et al. Delta virus infection and severe hepatitis. Ann Intern Med 1984; 100: 339-349.

6.- RIZZETO M, VERNE G, RECHIS S. Chronic hepatitis in carriers of hepatitis B surface antigen. With intrahepatic expression of delta antigen. An active and progressing disease unresponsive to immune suppressive treatment. Ann Intern Med 1983; 98: 437.

7.- FARCI P, SMEDILE A, LAVARINI C., et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute B hepatitis progressive to chronicity. Gastroenterology 1983; 85: 669-673.

8.- JULIAO RUIZ O. Prevalencia de antígeno de superficie "B" en Colombia. Biomédica INS Colombia,1991; 11: 56-60.

9.- FONSECA, JCF, GAYOTTO LCC, FERREIRA LCL et al. Labrea hepatitis- hepatitis B and Delta antigen expresion in liver tissue: report of three autopsy cases. Rev Inst Med Trop Sao Paulo 1985; 17: 224

10.- MENDEZ M, ARCE M, SÁNCHEZ S., y col. Prevalencia de marcadores serológicos de hepatitis vírica en diversos grupos de población del Perú. Bol Of Sanit Panam 1989; 106: 127-138.

11.- COLICHÓN YA. Distribución seroepidemiológica de la Hepatitis B y hepatitis Delta en diferentes comunidades indígenas de la Selva Peruana (Tesis doctoral). Lima, Perú: Universidad Peruana Cayetano Heredia, 1989.

12.- CABEZAS C. Epidemiología de las hepatitis Virales B y Delta en el Peru. Rev de Med Experimental 1997; 14: 57-61.

13.- VILDÓSOLA H, FARFAN G, COLAN E., et al. Prevalencia del antígeno de superficie del virus de hepatitis B en población general de Costa, Sierra y Selva del Perú. Reporte preliminar. Rev. Gastroen Peru 1990; 10: 96-1001.

14.- CABEZAS C, REATEGUI J, SUAREZ M; ROMERO G, CARRILLO C, et al. Hiperendemicity of HBV and Delta among Native communities of the Amazon Region of Peru. International Conference on Emerging Infectious Diseases. Abst 14.3, March 8-11,1998; Atlanta Georgia, USA.

15.- GASTELUMENDI R, BURSTEIN M, LEON BARUA R. Contribución al estudio de la hepatitis viral en dermoepidémica en Abancay. Ann de la Fac de Med 1960; XLIII: 629-50.

16.- ROLANDO N, FIGUEROA R, TACAÑO J, GUILLEN C, LIZARRAGA J, y HAYE J. Estudio clínico, bioquímico y anatomopatológico de los portadores de antígeno de superficie de la hepatitis B en Abancay. Diagnóstico 1983; 12: 5-17.

17.- CABEZAS C, RAMOS F, SANCHEZ J., et al. High prevalence of infection with hepatitis B and Delta in the children of Huanta-Ayacucho (Perú) Abtsr A286 IX TRIENNIAL INTERNATIONAL SYMPOSIUM ON VlRAL HEPATITIS AND LIVER DISEASE, April 21-25 1996 Rome, Italy.

18.- CABEZAS C, GOTUZZO E, ESCAMILLA J, PHILIPS I. Prevalencia de marcadores serológicos de hepatitis vira¡ A, B y Delta en escolares aparentemente sanos de Huanta (Perú). Rev. Gastroent Perú 1994; 14: 123-134.

19.- CABEZAS C, BARTALESI F. Causes of death related to liver diseases in Huanta-Perú a 32 years evaluation. Abtsr A313 IX TRIENNIAL INTERNATIONAL SYMPOSIUM ON VIRAL HEPATITIS AND LIVER DISEASE, April 21-25, 1996, Rome, Italy.

20.- CORONEL LG. Incidencia de marcadores de HBsAg en pacientes con diagnóstico clínico de hepatitis en el Hospital de Huanta-Ayacucho, 1985-1986. Tesis Bach. Biol. UNSCH.

21.- COLICHÓN A., GALVEZ J., y col. Hepatitisis No-A, No-B en el Perú- Estudio de marcadores serológicos en 100 pacientes con diagnóstico de hepatitis viral en Huanta. Diagnóstico, 1989; 24: 10-17.
22.- MCALEER WL, BUYNACK EB, MAIGETLER RZ., et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178-180.

23.- SZMUNESS W, STEVEN CE, HARLEY EJ., et al. Hepatitis B vaccine demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841.

24.- WONG VCW, IP HMH, REESINK HW et al. Prevention of the HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis immunoglobulin. Lancet 1984;i:921-926.

25.- DEL CAHNO R, GRROSHEIDE PM, VOOGD M, HUISMAN VM, HEIJTINK RA, SCHALM SW. Immunogenicity of 20 ug of recombinant DNA hepatitis B vaccine in healthy neonates: A comparison of three different vaccination schedules. Journal of Medical Virology 1993; 41: 30-34.

26.- PETRE J, VAN WIJNWNDAELE F, DE NEYS B, CONRATH K, VAN OPSTAL O., et al. Development of Hepatitis Vaccine from transformed yeast cells. Postgraduate Medical Journal 1987; 63 (Suplement 2): 73-81

27.- HALI JA, INSKIP HM, LOIK F CHOTARD J, VALL MAYANS M. Hepatitis B vaccine in the expanded programme of immunization: The Gambian experience. Lancet 1989; ii: 1057-60.

28.- PAHO/WHO. Progress report on hepatitis B vaccination in the Americas. En: Report of the PAHO Workshop on Viral Hepatitis Pre-Meeting to the 10th Annual Meeting of the EPI/Polio TAG. Río de Janeiro, Brasil, March 15, 1992.

29.- CHOTARS J, INSKIP H, JALI AJ, LOIK E et al. The Gambia Hepatitis Intervention Study: Follow-Up of a Cohort of Children Vaccinated against hepatitis B. The Journal of Infect Diseases 1992; 166: 764-8.

30.- MAHONEY FJ, WOODRUFF BA, ERBEN J, COLEMAN PJ, REID EC., et al. Effect of a Hepatitis B vaccination Program on Prevalence of hepatitis B Virus Infection. The Journal of Infectious Diseases 1993; 167: 203-7

31.- TABOR E, CAIRNS J, GERETY R, BAYLEY A. Nine Year Follow-Up Study of a plasma-Derived Hepatitis B Vaccine in a Rural African Setting 1993; 40: 204-209.

32 COURSAGET P, YVONNET B, RELYVELD EH, BARRES JL, DIOP-MAR 1, CHIRON JP. Simultaneus administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization programme: immune responses to diphtheria toxoid, tetanus toxoid, pertussis and hepatitis B surface antigen. Infect immun (1986; 51: 784-87)

33.- WHITTLE HC, INSKIP H, HALL AJ, MENDY M, DOWNES R, HOARE S. Vaccination against hepatitis B and protection against chronic viral carriage in the Gambia. Lancet 1991; 337:747-50.

34.- ANDRE FE, ZUCKERMAN A. Review: Protective of hepatitis B Vaccine in neonates. Journal of Medical Virology 1994;44:144-151

35.- FERNÁNDEZ BR, RIVERO D, ECHEVARRÍA B, MACHADO I. Costo beneficio de la vacunación contra hepatitis B en trabajadores de hospitales de Venezuela. Bol Of Sanit Panam 1991; 111: 16-23.

36.- MANGTANI P, HALI AJ, NORMAND CEM. Hepatitis B vaccination: The cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health 1995; 49: 238-244.

37.- CHANG MH, CHEN CJ, LAI MS, HSU HM, WU TC, KONG MS., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med, 1997; 336: 1906-7)

38.- CHIU HH, HUANG LM, LEE PI, SAFARY A, LEE CY. Diphteria, tetanus and whole cell pertusis vaccine combined with hepatitis B vaccines: a comparison of two doses. Pediatr Infect Dis J 1998; 17: 206-11

39.- SHIH HH, CHANG MH, HSU HY, LEE PI, NI YH, CHEN DS. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatr Infect Dis J 1999; 18: 427-32)

40.- CABEZAS C, ROMERO J, ROMERO G, SUÁREZ M. Bajo riesgo de transmisión vertical del virus de hepatitis B en un área hiperendémica del Perú. Bol Soc Per Enf Infecc y Tropic. Abst B.26,1997; 6: 51.

41.- LEE CY, LEE PI, HUANG LM, CHEN JM, CHANG MH. A simplified schedule to integrate the hepatitis B vaccine on to an expanded program of imnunization in endemic countries. J Pediatr 1997; 130: 981-6.

42.- HSU HM, LU CF, LEE SC, LIN SR, CHEN IDS. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: The effect of hepatitis B mass vaccination. J Infect Dis 1999; 179: 367-70

43.- CABEZAS C, ECHEVARRÍA C, GOTUZZO E. Programa piloto de inmunización contra hepatitis viral B, integrado al Programa Ampliado de Inmunización (PAI) en Abancay (Perú). Rev Gastroent. Perú, 1995; 15:215222.

44.- CABEZAS C, SÁNCHEZ J, ANAYA E. Transmisión Horizontal de hepatitis Vira¡ B en población desplazada de un área hiperendémica a sus contactos en un área de baja endemicidad del Perú. Rev Gastroent Perú, 1997; 17:235-142.

REGRESAR AL ARTÍCULO

Regresar